For Sarah Cannon, 2014 was a year of significant achievements — all supporting its goal of redefining cancer care around the world through clinical excellence and cutting-edge research. In the past 12 months, Sarah Cannon, the global cancer enterprise of HCA, and Sarah Cancer Research Institute, Sarah Cannon’s research arm, have continued to be at the forefront of drug research and excellent patient care, by sharing knowledge and findings in presentations at international conferences and in medical journals.
What does this mean to the Sarah Cannon patient? Quite simply, said Holli Hutcheson Dilks, Ph.D., Director, Personalized Medicine Operations at Sarah Cannon Research Institute, “we can offer the very latest options for clinical therapeutics to our patients — from state-of-the-art treatments to clinical trial and therapeutic options such as targeted therapies or immunotherapies. We are intimately involved in the latest, targeted therapies that are being developed and can offer them to our patients.”
Participation in Drug Approvals
“Since 2012, 58 drugs have gained U.S. Food and Drug Administration (FDA) approval, and of those, Sarah Cannon participated in clinical trials for more than three-quarters of them,” said Suzanne Jones, Pharm.D., Sarah Cannon Research Institute Scientific Director. “Of the 19 hematology/oncology approvals by the FDA in 2014, Sarah Cannon participated in clinical trials with 13 of the agents prior to the original FDA approval.”
Among those with which Sarah Cannon was involved included drugs for:
- Metastatic non-small-cell lung cancer
- Platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
- Unresectable or metastatic melanoma
- Persistent, recurrent or metastatic cervical cancer
“Some of the drugs are first indication approvals, meaning they are approved for a specific type of cancer,” explained Jones, “while others are subsequent indication approvals, meaning the drug was first approved for one type of cancer, but has now been approved for another type of cancer or in another disease setting.”
Cancer Research Presentations and Publications
While research and clinical trials are critically important, it’s also essential that the information be shared among the cancer community. To that end, Sarah Cannon participates in numerous conferences such as American Society of Clinical Oncology (ASCO) Annual Meeting , 2014 ASH Meeting and Exposition , BMT Tandem and the 2014 San Antonio Breast Cancer Symposium . as well as offering facility-based treatment planning conferences within the Sarah Cannon Cancer Network of Excellence.
Sarah Cannon leadership has also presented more than 230 abstracts in 2014 alone and published more than 100 manuscripts in leading peer-reviewed journals, including the New England Journal of Medicine, Blood and the Journal of Clinical Oncology. This not only reinforces Sarah Cannon’s commitment to being at the forefront of advancing novel therapies for cancer care but also reassures our patients that the treatment we provide is the most appropriate.
Sarah Cannon is continuing to actively participate in clinical trials and research to expand treatment options for patients now and in the future. This means that Sarah Cannon will continue to offer “a diverse and extensive menu of therapeutic options,” said Dilks. “This enables us to provide our patients with the most appropriate and individualized treatment options based on the latest research.”